Key Points Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The ...

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

The first oral pill for obstructive sleep apnea could be around the corner after company Apnimed reported positive results ...

Tirzepatide may confer larger increases in testosterone levels among men with metabolic hypogonadism than testosterone ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

Roughly one in three preteens and teens ages 12 to 17 in the United States had prediabetes in 2023, according to new data ...

Positive topline results of the LunAIRo trial put AD109 on track for approval as the first oral sleep apnoea medication.

GLP-1 blockbusters like semaglutide and tirzepatide are widely used for diabetes and weight loss but come with some nasty ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

Roche is considering selling its prescription medicines in the U.S. directly to consumers to lower costs for patients as part ...

From supplements to injectables to belly-fat blasting beverages, there are plenty of products that claim to speed weight loss ...